Sat.Mar 11, 2023 - Fri.Mar 17, 2023

article thumbnail

Novo Nordisk Follows Eli Lilly’s Lead, Lowering Insulin Prices up to 75%

MedCity News

Novo Nordisk can afford the price cuts prices to several branded and non-branded insulins. Flattening revenue for the pharmaceutical giant’s insulin products is offset by demand for diabetes and obesity drugs from its semaglutide franchise, which continues to grow by leaps and bounds.

Leads 98
article thumbnail

AstraZeneca employees fight layoffs in India as drugmaker shifts 'strategic priorities'

Fierce Pharma

AstraZeneca employees fight layoffs in India as drugmaker shifts 'strategic priorities' aliu Thu, 03/16/2023 - 09:54

306
306
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Mass spectrometry software can link different data types

European Pharmaceutical Review

The latest version of software tool MZmine, which aids analysis of mass spectrometry data, has been released. Using this third generation software, scientists can analyse large volumes of data from mass spectrometry, processing thousands of samples within minutes to hours. [the newest version can process] thousands of samples within minutes to hours.” It is the first tool with an entire data processing pipeline that integrates liquid chromatography (LC)-ion mobility spectrometry (IMS)-MS a

article thumbnail

Scientists Grow Electrodes Inside The Body

Medgadget

Researchers at Linköping University in Sweden have developed a method whereby the body can ‘grow its own’ electrodes. The minimally invasive technique involves injecting a hydrogel that is laden with enzymes into target tissues. The enzymes interact with molecules that are present in the tissue to change the structure of the gel and allow it to become electrically conductive.

Medical 128
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Pfizer’s Migraine Drug Approval Triggers $475M Payment to Royalty Pharma

MedCity News

Royalty Pharma’s milestone payment from the approval of Pfizer migraine drug Zavzpret stems from financing deals struck with the therapy’s previous developer, Biohaven Pharmaceuticals. Royalty Pharma is also in line to receive royalty payments going beyond the next decade.

Pharma 119
article thumbnail

Astellas, Pfizer look to broaden Xtandi’s patient base with new prostate cancer win after 8 years

Fierce Pharma

Astellas, Pfizer look to broaden Xtandi’s patient base with new prostate cancer win after 8 years aliu Fri, 03/17/2023 - 10:22

Patients 289

More Trending

article thumbnail

Brazil’s ANVISA approves Takeda’s dengue vaccine candidate Qdenga

Pharmaceutical Technology

The National Health Surveillance Agency (ANVISA) in Brazil has granted approval for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). The vaccine has received approval for preventing dengue disease in people aged four years to 60 years. Qdenga has been developed based on a live-attenuated dengue serotype 2 virus that offers the genetic backbone for four dengue virus serotypes and is designed to provide protection against any of these.

article thumbnail

What Role Could ChatGPT Have in Clinical Trials? A Bigger One Than You Might Think

MedCity News

Already, ChatGPT has been named as a co-author on at least four research papers. With proper management, AI generation could be an invaluable tool in clinical research—but only if we are mindful of the potential risks and biases that may arise from their usage and ensure transparency, fairness, and accountability in their use.

article thumbnail

Novo Nordisk hit with two-year suspension from UK pharma group after online marketing breaches

Fierce Pharma

Novo Nordisk hit with two-year suspension from UK pharma group after online marketing breaches fkansteiner Thu, 03/16/2023 - 09:00

Marketing 279
article thumbnail

GOSH and Leucid to manufacture novel CAR T therapy

European Pharmaceutical Review

In a first-of-its-kind commercial agreement, Great Ormond Street Hospital NHS Foundation Trust (GOSH) will work with Leucid Bio to manufacture LEU011, a lateral Chimeric Antigen Receptor (CAR) targeting NKG2D ligands. The CAR T therapy will be used in clinical studies for solid tumours and haematological malignancies. Under the agreement the parties will work together at state-of-the-art cleanroom facilities at the Zayed Centre for Research into Rare Disease in Children.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Tapping into digital therapeutics to improve neurological outcomes

Pharmaceutical Technology

As the field of digital therapeutics continues to broaden, specific uses in mental health and neurology are increasingly making headway for patients and on the market. At the same time, experts are saying developers in the field need to double down on securing clinical data to allow for its continued maturation. Companies are testing the use of digital platforms along with pharmacological treatments.

article thumbnail

Perspectum Completes $55M Series C to Improve Metabolic Disease Diagnosis

MedCity News

Perspectum — a company that makes medical imaging devices designed to improve the diagnosis of metabolic diseases and cancer — recently announced the second close of its $55 million Series C funding round. Its flagship product is a diagnostic tool that assesses and monitors chronic liver disease.

Medical 119
article thumbnail

After $3.4B deal and EU withdrawal, Novartis looks to sell Xiidra: Bloomberg

Fierce Pharma

After $3.

279
279
article thumbnail

Owlstone Medical collaborates with Bicycle Therapeutics

PharmaTimes

Duo team up for the development of antigen-targeted probes for early cancer detection

Medical 111
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Novel small molecule drug facilitates leukaemia remission

European Pharmaceutical Review

New targeted drug revumenib facilitated complete response in around 40 percent of patients with acute leukaemia subtypes, according to data in a new pair of studies ( 1 ) and ( 2 ) published in Nature. The two genetic subtypes of acute leukaemia involved in this research are “driven by a rearrangement of the MLL1 gene or a mutation in the NPM1 gene.

Patients 105
article thumbnail

AHIP-led Coalition Aims To Reduce Coverage Losses Amid Pending Medicaid Redeterminations

MedCity News

AHIP and several other healthcare organizations launched the Connecting to Coverage Coalition last week in an effort to make the upcoming Medicaid redetermination process run smoothly. The coalition’s website includes studies on Medicaid redeterminations and frequently asked questions for enrollees. AHIP also released a report that shows 53.6% of those who will lose coverage will transition to employer-sponsored insurance and 21.2% will become uninsured.

Insurance 119
article thumbnail

With $43B buyout, Pfizer sees cancer specialist Seagen as a 'goose' laying 'golden eggs'

Fierce Pharma

With $43B buyout, Pfizer sees cancer specialist Seagen as a 'goose' laying 'golden eggs' kdunleavy Mon, 03/13/2023 - 10:16

279
279
article thumbnail

Immutep reveals initiation of pivotal Efti study

PharmaTimes

The clinical trial also involves paclitaxel in the treatment of metastatic breast cancer

108
108
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Pharmanovia signs licence deal for Aeterna Zentaris’ Ghryvelin

Pharmaceutical Technology

Pharmanovia and Aeterna Zentaris have entered an exclusive licensing agreement for the latter’s medicine Ghryvelin (macimorelin). Under the deal, Pharmanovia will acquire the exclusive rights and license to commercialise Ghryvelin in the EEA and the UK from Consilient Health. Ghryvelin is used for the diagnosis of Adult Growth Hormone Deficiency (AGHD), a rare and serious condition, as well as for Childhood Onset Growth Hormone Deficiency (CGHD), if approved.

Medicine 105
article thumbnail

Joint Commission CEO Wants to “Dispel the Myth” that Decarbonizing Healthcare Is Costly

MedCity News

Some actions to reduce healthcare’s carbon footprint actually will save money, said Jonathan Perlin, CEO of the nonprofit national and international accrediting organization.

article thumbnail

Amgen cuts 450 workers, cites drug pricing pressure and inflation

Fierce Pharma

Amgen cuts 450 workers, cites drug pricing pressure and inflation zbecker Fri, 03/17/2023 - 10:53

275
275
article thumbnail

PBD Biotech reveals vital update to TB test

PharmaTimes

Lyophilized PCR reaction bead reduces the cost of transport and extends shelf life for the test

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Talem and Libera Bio partner for discovery of AI-driven antibodies

Pharmaceutical Technology

Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The partnership will use nanotechnology, which was proven in vivo, for providing antibodies inside tumour cells and provides a potential solution to address the medical challenge.

Pharma 104
article thumbnail

Why Point-of-Care Diagnostic Filtering, Interoperability Are Essential in the Age of TEFCA, QHINs

MedCity News

Without a new set of tools that clinicians can access at the point of care, the availability of information from QHINs will increase provider burdens because they will struggle to find the information needed to evaluate a patient, take action, complete documentation, and move to the next patient.

Patients 116
article thumbnail

Moderna, riding COVID success and busy growing its pipeline, hikes pay of CEO Bancel to $19.4M

Fierce Pharma

Moderna, riding COVID success and busy growing its pipeline, hikes pay of CEO Bancel to $19.

264
264
article thumbnail

IIH headaches could be treated with exenatide

PharmaTimes

The type 2 diabetes therapy is being tested on patients in a phase 2 clinical trial

Patients 103
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

How Patients Can Achieve True Adherence – Two Elements For the Path Forward

Impetus Digital

This is a guest article written by Luke Buchanan, CEO of Redi.Health , and does not necessarily reflect the views and values of Impetus Digital. When we think of adherence in the medical world, it’s often simplified to something along the lines of the degree to which a patient correctly follows medical advice. It’s a simple statement with many, many moving parts, especially when we’re talking about patients with multiple chronic conditions.

Patients 102
article thumbnail

Preserve Access to Home Oxygen Therapy Post-Pandemic

MedCity News

CMS should honor its commitment to Medicare beneficiaries, especially those who began home respiratory therapy under the PHE, without requiring them to “restart” the documentation process. Requiring requalification would also be a nightmare for physicians who are already overwhelmed with patient demands.

article thumbnail

Novo Nordisk follows Eli Lilly's lead, slashing insulin prices in the US

Fierce Pharma

Novo Nordisk follows Eli Lilly's lead, slashing insulin prices in the US kdunleavy Tue, 03/14/2023 - 10:56

Leads 264
article thumbnail

NICE approves funding for Novartis gene therapy

PharmaTimes

Funding is for onasemnogene abeparvovec and concerns babies with spinal muscular atrophy

102
102
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time